Neogen Chemicals Limited share price
NSE: NEOGEN · ISIN INE136S01016
Key numbers
- Market cap
- ₹ 7,166 Cr
- Current price
- ₹ 2,385.20
- 52-week high / low
- ₹ 2,500 / 967
- Stock P/E
- 183.1
- Book value
- ₹ 309.6
- Dividend yield
- 0.04%
- ROCE
- 5.7%
- ROE
- 3.6%
- Debt to equity
- 1.71
- Sales growth (3 yrs)
- 8.7%
- Profit growth (3 yrs)
- -16.8%
- 1-year return
- 55.2%
About Neogen Chemicals Limited
Neogen Chemicals Limited engages in the manufacture and sale of specialty chemicals in India. It offers organo bromine compounds, such as alkyl bromide compounds, dibromoalkane compounds, bromo chloro alkanes, bromine derivatives of organoacids, bromoacid ester compounds, aromatic bromine derivatives, cyclic bromine derivatives, and speciality bromo fluro derivatives; speciality chloro compounds comprising unsaturated bromine derivatives, bromo hydroxy derivatives, and other compounds; and organo lithium compounds, including n-butyl lithium, lithium hexamethyldisilazide, lithium tetrahydride borate, lithium diisopropylamide, lithium tri-(t-butoxy) aluminium hydride, hexyl lithium, methyl lithium, and phenyl lithium. The company also provides inorganic chemicals comprising inorganic bromine compounds and lithium salts; grignard reagents; advance intermediates; and chemistries, such as alkylation, amination, oxidation, dehalogenation, silylation, anhydrous HF and HBr reactions, halex reaction, suzuki coupling, hydrogenation, and biocatalysis. It serves pharmaceuticals, agrochemicals, electronics, water treatment, construction, polymers, flavours & fragrances and energy storage. The…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 187 | 209 | 220 | 247 | 250 |
| Operating profit | 32 | 30 | 32 | 44 | 49 |
| Net profit | 10 | 3 | 4 | 11 | 17 |
| EPS (₹) | 3.89 | 1.28 | 1.40 | 4.32 | 6.29 |
Concall summary (2026-08-01)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Updates on battery chemicals and Neogen Ionics performance Neogen Ionics delivered a robust performance in Q1 FY27, generating INR 19 crore in revenue compared to INR 5 crore in Q1 FY26 and delivering over 50% of the entire previous year's revenue in just three months.
- Commissioning the facility for electrolyte is targeted for H1 FY27 and lithium electrolyte salts remain targeted for H2 FY27.
Growth & demand
- This growth was driven by volume growing across our core business verticals, sustained customer demand, and our highest ever quarterly revenue recorded in both organo-lithium and battery chemicals portfolio.
- In Q1 FY27, on a consolidated basis, we recorded revenue of INR 250 crore, registering a robust growth of 34% year-on-year.
Margins & costs
- EBITDA grew by 53% year-on- year to INR 48 crore with EBITDA margins expanding by 260 basis points to 19.3%.
- We have successfully initiated cost pass-through mechanisms with customers across key raw materials and input costs, such as, utilities, freight, and packaging to safeguard our operating margins.
Capex & expansion
- Margin expansion was achieved despite temporary expenses related to Dahej plant rebuild, toll manufacturing and job work-related expenses, initial expansion cost at Neogen Ionics, and freight spikes.
- Depreciation was higher at INR 8.2 crore, up 42% due to smaller CAPEXes which we had added during the year.
Balance sheet & cash
- Our net claim receivable as on date stands as INR 186 crore on a consolidated basis and we continue to engage closely with insurers to expedite final settlement against the same, followed by some additional recoveries under various other insurance policies, such as, loss on profit.
- Backed by solid customer demand, improving operational leverage, and disciplined capital allocation, we are happy to improve our standalone guidance from INR 875 crore to INR 950 crore to INR 950 crore to INR 1,050 crore in the revised range.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.